Asciminib (ABL001), a novel allosteric BCR::ABL1 inhibitor, targets the myristoyl binding pocket, with promising response in CML-CP third-line treatment after ≥2 previous TKIs [8]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.